Pfizer Inc.: peers
Pfizer Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Pfizer Inc.base PFE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Bristol-Myers Squibb Company BMY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Amgen Inc. AMGN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Merck & Co., Inc. MRK · 🇺🇸 US Percentile in Healthcare Percentile in USA | Gilead Sciences, Inc. GILD · 🇺🇸 US Percentile in Healthcare Percentile in USA | AbbVie Inc. ABBV · 🇺🇸 US Percentile in Healthcare Percentile in USA | Biogen Inc. BIIB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Zoetis Inc. ZTS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $170.7 BOct 30, 2026 · Market data5th of 8 | $125.5 BOct 30, 2026 · Market data6th of 8 | $249.2 BOct 30, 2026 · Market data3rd of 8 | $359.8 BOct 19, 2026 · Market data2nd of 8 | $193.5 BOct 26, 2026 · Market data4th of 8 | $514.0 BOct 30, 2026 · Market data1st of 8 | $37.5 BOct 23, 2026 · Market data7th of 8 | $32.9 BOct 26, 2026 · Market data8th of 8 | $182.1 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $62.6 BFY2025 · SEC2nd of 7 | $48.2 BFY2025 · SEC4th of 7 | $36.8 BFY2025 · SEC5th of 7 | $65.0 BFY2025 · SEC1st of 7 | —— | $61.2 BFY2025 · SEC3rd of 7 | $9.9 BFY2025 · SEC6th of 7 | $9.5 BFY2025 · SEC7th of 7 | $48.2 B7 ranked |
| Net income (Higher is better) | $7.8 BFY2025 · SEC2nd of 7 | $7.1 BFY2025 · SEC4th of 7 | $7.7 BFY2025 · SEC3rd of 7 | $18.3 BFY2025 · SEC1st of 7 | —— | $4.2 BFY2025 · SEC5th of 7 | $1.3 BFY2025 · SEC7th of 7 | $2.7 BFY2025 · SEC6th of 7 | $7.1 B7 ranked |
| Employees (Better neither way: ranked highest first) | 75,000December 31, 2025 · Profile1st of 8 | 32,500December 31, 2025 · Profile4th of 8 | 25,200As on Dec-2022 · Profile5th of 8 | 75,000December 31, 2025 · Profile1st of 8 | 17,000As on 2022 · Profile6th of 8 | 57,000December 31, 2025 · Profile3rd of 8 | 7,500December 31, 2025 · Profile7th of 8 | 1,700December 31, 2025 · Profile8th of 8 | 28,8508 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | -1.6%FY2025 · SEC7th of 722nd25th | -0.2%FY2025 · SEC6th of 726th28th | +9.9%FY2025 · SEC1st of 749th61st | +1.3%FY2025 · SEC5th of 729th33rd | ———— | +8.6%FY2025 · SEC2nd of 746th57th | +2.2%FY2025 · SEC4th of 731st36th | +2.3%FY2025 · SEC3rd of 731st36th | +2.2%7 ranked |
| Revenue growth, 3 years a year (Higher is better) | -14.8%FY2025 · SEC7th of 710th6th | +1.4%FY2025 · SEC5th of 731st38th | +11.8%FY2025 · SEC1st of 758th73rd | +3.1%FY2025 · SEC3rd of 737th45th | ———— | +1.8%FY2025 · SEC4th of 732nd39th | -0.9%FY2025 · SEC6th of 725th29th | +5.4%FY2025 · SEC2nd of 743rd54th | +1.8%7 ranked |
| Earnings per share growth (Higher is better) | -3.5%FY2025 · SEC5th of 632nd33rd | ———— | +88.2%FY2025 · SEC1st of 686th88th | +8.0%FY2025 · SEC3rd of 649th48th | ———— | -1.3%FY2025 · SEC4th of 635th36th | -21.4%FY2025 · SEC6th of 621st21st | +10.1%FY2025 · SEC2nd of 651st51st | +3.4%6 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 74.3%FY2025 · SEC3rd of 773rd86th | 71.1%FY2025 · SEC5th of 769th83rd | 67.3%FY2025 · SEC7th of 764th80th | 74.8%FY2025 · SEC2nd of 774th87th | ———— | 70.2%FY2025 · SEC6th of 769th83rd | 75.7%FY2025 · SEC1st of 775th88th | 71.8%FY2025 · SEC4th of 771st84th | 71.8%7 ranked |
| Operating margin (Higher is better) | ———— | ———— | 24.7%FY2025 · SEC1st of 292nd90th | ———— | ———— | 24.6%FY2025 · SEC2nd of 292nd90th | ———— | ———— | 24.7%2 ranked |
| Net margin (Higher is better) | 12.4%FY2025 · SEC6th of 782nd79th | 14.6%FY2025 · SEC4th of 785th83rd | 21.0%FY2025 · SEC3rd of 791st90th | 28.1%FY2025 · SEC2nd of 793rd94th | ———— | 6.9%FY2025 · SEC7th of 773rd67th | 13.1%FY2025 · SEC5th of 783rd81st | 28.2%FY2025 · SEC1st of 793rd94th | 14.6%7 ranked |
| Free cash flow margin (Higher is better) | 14.5%FY2025 · SEC7th of 780th80th | 26.6%FY2025 · SEC2nd of 794th94th | 22.0%FY2025 · SEC4th of 791st90th | 19.0%FY2025 · SEC6th of 786th87th | ———— | 29.1%FY2025 · SEC1st of 796th95th | 20.7%FY2025 · SEC5th of 789th89th | 24.1%FY2025 · SEC3rd of 792nd92nd | 22.0%7 ranked |
| Return on equity (Higher is better) | 8.9%FY2025 · SEC5th of 680th61st | 40.5%FY2025 · SEC3rd of 696th95th | 106.1%FY2025 · SEC1st of 699th99th | 36.9%FY2025 · SEC4th of 696th94th | ———— | ———— | 7.4%FY2025 · SEC6th of 678th57th | 65.3%FY2025 · SEC2nd of 698th97th | 38.7%6 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | 14.4%FY2025 · SEC2nd of 261st64th | ———— | ———— | 16.0%FY2025 · SEC1st of 266th69th | ———— | ———— | 15.2%2 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 42.3×price Oct 30, 2026 · Market data4th of 766th83rd | 13.6×price Oct 30, 2026 · Market data6th of 719th32nd | 26.5×price Oct 30, 2026 · Market data5th of 745th66th | 146.7×price Oct 19, 2026 · Market data1st of 792nd96th | ———— | 49.7×price Oct 30, 2026 · Market data3rd of 771st87th | 108.0×price Oct 23, 2026 · Market data2nd of 790th95th | 13.1×price Oct 26, 2026 · Market data7th of 718th30th | 42.3×7 ranked |
| Price to sales (Better neither way: ranked highest first) | 2.7×price Oct 30, 2026 · Market data7th of 841st56th | 2.5×price Oct 30, 2026 · Market data8th of 839th54th | 6.4×price Oct 30, 2026 · Market data2nd of 863rd82nd | 5.3×price Oct 19, 2026 · Market data4th of 858th79th | 6.3×price Oct 26, 2026 · Market data3rd of 862nd82nd | 7.8×price Oct 30, 2026 · Market data1st of 868th86th | 3.6×price Oct 23, 2026 · Market data5th of 850th68th | 3.5×price Oct 26, 2026 · Market data6th of 848th66th | 4.5×8 ranked |
| Price to book (Better neither way: ranked highest first) | 2.0×price Oct 30, 2026 · Market data7th of 738th47th | 6.8×price Oct 30, 2026 · Market data5th of 775th83rd | 28.8×price Oct 30, 2026 · Market data1st of 795th97th | 6.8×price Oct 19, 2026 · Market data4th of 776th83rd | 8.5×price Oct 26, 2026 · Market data3rd of 781st87th | ———— | 2.1×price Oct 23, 2026 · Market data6th of 739th49th | 9.6×price Oct 26, 2026 · Market data2nd of 783rd89th | 6.8×7 ranked |
| Free cash flow yield (Higher is better) | 5.3%price Oct 30, 2026 · Market data4th of 888th68th | 10.2%price Oct 30, 2026 · Market data1st of 894th87th | 3.3%price Oct 30, 2026 · Market data8th of 879th55th | 3.4%price Oct 19, 2026 · Market data7th of 880th56th | 4.9%price Oct 26, 2026 · Market data5th of 887th66th | 3.5%price Oct 30, 2026 · Market data6th of 880th56th | 5.5%price Oct 23, 2026 · Market data3rd of 888th69th | 6.9%price Oct 26, 2026 · Market data2nd of 891st76th | 5.1%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.7×FY2025 · SEC2nd of 665th55th | 2.4×FY2025 · SEC4th of 691st89th | 6.3×FY2025 · SEC6th of 696th96th | 0.9×FY2025 · SEC3rd of 673rd64th | ———— | ———— | 0.3×FY2025 · SEC1st of 642nd33rd | 2.6×FY2025 · SEC5th of 692nd89th | 1.7×6 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | 3.2×FY2025 · SEConly one with it70th65th | ———— | ———— | ———— | ———— | ———— | 3.2×— |
| Interest cover (Higher is better) | ———— | ———— | 3.3×FY2025 · SEC2nd of 283rd68th | ———— | ———— | 5.2×FY2025 · SEC1st of 287th75th | ———— | ———— | 4.3×2 ranked |
| Piotroski F-score (Higher is better) | 5 of 9FY2025 · SEC5th of 7 | 8 of 9FY2025 · SEC1st of 7 | 7 of 9FY2025 · SEC3rd of 7 | 4 of 9FY2025 · SEC6th of 7 | —— | 8 of 9FY2025 · SEC1st of 7 | 4 of 9FY2025 · SEC6th of 7 | 6 of 9FY2025 · SEC4th of 7 | 6.0 of 97 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 11 of 21FY2025 · Scorecard5th of 7 | 17 of 24FY2025 · Scorecard2nd of 7 | 20 of 30FY2025 · Scorecard3rd of 7 | 16 of 24FY2025 · Scorecard3rd of 7 | —— | 13 of 27FY2025 · Scorecard6th of 7 | 9 of 19FY2025 · Scorecard7th of 7 | 18 of 23FY2025 · Scorecard1st of 7 | 67% passed7 ranked |
| Valuation checks (Higher is better) | 3 of 6FY2025 · Scorecard2nd of 7 | 5 of 6FY2025 · Scorecard1st of 7 | 1 of 6FY2025 · Scorecard5th of 7 | 0 of 6FY2025 · Scorecard6th of 7 | —— | 0 of 6FY2025 · Scorecard6th of 7 | 2 of 6FY2025 · Scorecard4th of 7 | 3 of 6FY2025 · Scorecard2nd of 7 | 33% passed7 ranked |
| Growth checks (Higher is better) | 0 of 6FY2025 · Scorecard7th of 7 | 2 of 6FY2025 · Scorecard4th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 5 of 6FY2025 · Scorecard3rd of 7 | —— | 2 of 6FY2025 · Scorecard4th of 7 | 1 of 6FY2025 · Scorecard6th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | 2 of 3FY2025 · Scorecard5th of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 5 of 6FY2025 · Scorecard3rd of 7 | 3 of 3FY2025 · Scorecard1st of 7 | —— | 4 of 5FY2025 · Scorecard4th of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 80% passed7 ranked |
| Financial health checks (Higher is better) | 3 of 3FY2025 · Scorecard1st of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 3 of 6FY2025 · Scorecard7th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | —— | 3 of 4FY2025 · Scorecard4th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 75% passed7 ranked |
| Shareholder returns checks (Higher is better) | 3 of 3FY2025 · Scorecard1st of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 5 of 6FY2025 · Scorecard4th of 7 | 5 of 6FY2025 · Scorecard4th of 7 | —— | 4 of 6FY2025 · Scorecard7th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard6th of 7 | 83% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 66.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 80.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 81.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 78.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 86.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 74.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 94.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 93.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 80.7%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 2,9082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 2,5622026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 3,2632026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 3,9602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 2,3492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 4,2722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 1,0592026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 1,3572026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 2,7358 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +1.6 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +3.2 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +3.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +2.3 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +4.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +2.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | +5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | -1.2 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +2.7 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | 4.0%FY2025 · SEC1st of 491st79th | 2.1%FY2025 · SEC4th of 471st49th | 2.3%FY2025 · SEC2nd of 479th54th | ———— | 2.3%FY2025 · SEC2nd of 479th54th | ———— | ———— | 2.3%4 ranked |
| Shareholder yield (Higher is better) | ———— | 4.0%FY2025 · SEC2nd of 570th59th | 2.1%FY2025 · SEC5th of 548th35th | 3.7%FY2025 · SEC3rd of 565th56th | ———— | 2.5%FY2025 · SEC4th of 552nd40th | ———— | 9.8%FY2025 · SEC1st of 590th88th | 3.7%5 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | 71.5%FY2025 · SEC2nd of 489th76th | 66.5%FY2025 · SEC3rd of 483rd73rd | 44.8%FY2025 · SEC4th of 472nd58th | ———— | 275.8%FY2025 · SEC1st of 498th97th | ———— | ———— | 69.0%4 ranked |
| Dividend per share (Better neither way: ranked highest first) | $1.72FY2025 · SEC6th of 6 | $2.49FY2025 · SEC4th of 6 | $9.66FY2025 · SEC1st of 6 | $3.28FY2025 · SEC3rd of 6 | —— | $6.65FY2025 · SEC2nd of 6 | —— | $2.03FY2025 · SEC5th of 6 | $2.886 ranked |
| Years of dividend raises (Higher is better) | 15to 2025 · SEC2nd of 7 | 16to 2025 · SEC1st of 7 | 12to 2025 · SEC4th of 7 | 15to 2025 · SEC2nd of 7 | 10to 2025 · SEC6th of 7 | 3to 2025 · SEC7th of 7 | —— | 12to 2025 · SEC4th of 7 | 127 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Pfizer Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bristol-Myers Squibb Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Amgen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merck & Co., Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Gilead Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AbbVie Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biogen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zoetis Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Pfizer Inc. | — | — | — |
| Bristol-Myers Squibb Company | — | — | — |
| Amgen Inc. | 24.7%FY2025 | 92nd percentile in Healthcaremedian -7.8%, 678 companies | 90th percentile in USAmedian 3.4%, 2,607 companies |
| Merck & Co., Inc. | — | — | — |
| Gilead Sciences, Inc. | — | — | — |
| AbbVie Inc. | 24.6%FY2025 | 92nd percentile in Healthcaremedian -7.8%, 678 companies | 90th percentile in USAmedian 3.4%, 2,607 companies |
| Biogen Inc. | — | — | — |
| Zoetis Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Pfizer Inc. | Bristol-Myers Squibb Company | Amgen Inc. | Merck & Co., Inc. | Gilead Sciences, Inc. | AbbVie Inc. | Biogen Inc. | Zoetis Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $62.6 BSEC2nd | $48.2 BSEC4th | $36.8 BSEC5th | $65.0 BSEC1st | $29.4 BSEC6th | $61.2 BSEC3rd | $9.9 BSEC7th | $9.5 BSEC8th |
| 2024 | $63.6 BSEC2nd | $48.3 BSEC4th | $33.4 BSEC5th | $64.2 BSEC1st | $28.8 BSEC6th | $56.3 BSEC3rd | $9.7 BSEC7th | $9.3 BSEC8th |
| 2023 | $59.6 BSEC2nd | $45.0 BSEC4th | $28.2 BSEC5th | $60.1 BSEC1st | $27.1 BSEC6th | $54.3 BSEC3rd | $9.8 BSEC7th | $8.5 BSEC8th |
| 2022 | $101.2 BSEC1st | $46.2 BSEC4th | $26.3 BSEC6th | $59.3 BSEC2nd | $27.3 BSEC5th | $58.1 BSEC3rd | $10.2 BSEC7th | $8.1 BSEC8th |
| 2021 | $81.3 BSEC1st | $46.4 BSEC4th | $26.0 BSEC6th | $48.7 BSEC3rd | $27.3 BSEC5th | $56.2 BSEC2nd | $11.0 BSEC7th | $7.8 BSEC8th |
| 2020 | $41.7 BSEC3rd | $42.5 BSEC2nd | $25.4 BSEC5th | $41.5 BSEC4th | $24.7 BSEC6th | $45.8 BSEC1st | $13.4 BSEC7th | $6.7 BSEC8th |
| 2019 | $40.9 BSEC1st | $26.1 BSEC4th | $23.4 BSEC5th | $39.1 BSEC2nd | $22.4 BSEC6th | $33.3 BSEC3rd | $14.4 BSEC7th | $6.3 BSEC8th |
| 2018 | $40.8 BSEC2nd | $22.6 BSEC5th | $23.7 BSEC4th | $42.3 BSEC1st | $22.1 BSEC6th | $32.8 BSEC3rd | $13.5 BSEC7th | $5.8 BSEC8th |
| 2017 | $52.5 BSEC1st | $20.8 BSEC6th | $22.8 BSEC5th | $40.1 BSEC2nd | $26.1 BSEC4th | $28.2 BSEC3rd | $12.3 BSEC7th | $5.3 BSEC8th |
| 2016 | $52.8 BSEC1st | $19.4 BSEC6th | $23.0 BSEC5th | $39.8 BSEC2nd | $30.4 BSEC3rd | $25.6 BSEC4th | $11.4 BSEC7th | $4.9 BSEC8th |
| 2015 | $48.9 BSEC1st | $16.6 BSEC6th | $21.7 BSEC5th | $39.5 BSEC2nd | $32.6 BSEC3rd | $22.9 BSEC4th | $10.8 BSEC7th | $4.8 BSEC8th |
| 2014 | $49.6 BSEC1st | $15.9 BSEC6th | $20.1 BSEC4th | $42.2 BSEC2nd | $24.9 BSEC3rd | $20.0 BSEC5th | $9.7 BSEC7th | $4.8 BSEC8th |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Pfizer Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Bristol-Myers Squibb CompanyBMY · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $125.5 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125.5 B (Oct 30, 2026) · revenue $48.2 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Amgen Inc.AMGN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $249.2 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $249.2 B (Oct 30, 2026) · revenue $36.8 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Merck & Co., Inc.MRK · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $359.8 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $359.8 B (Oct 19, 2026) · revenue $65.0 B (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Gilead Sciences, Inc.GILD · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $193.5 B market cap against $170.7 B · Same country: USAMarket cap $193.5 B (Oct 26, 2026) · revenue $29.4 B (year to December 2025)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- AbbVie Inc.ABBV · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $514.0 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $514.0 B (Oct 30, 2026) · revenue $61.2 B (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)In the group
- Biogen Inc.BIIB · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $37.5 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $37.5 B (Oct 23, 2026) · revenue $9.9 B (year to December 2025)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)In the group
- Zoetis Inc.ZTS · 🇺🇸 USASame industry: Pharmaceutical · 5.2× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32.9 B (Oct 26, 2026) · revenue $9.5 B (year to December 2025)89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)In the group
- Eli Lilly and CompanyLLY · 🇺🇸 USASame industry: Pharmaceutical · 7.0× larger by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.20 T (Oct 26, 2026) · revenue $65.2 B (year to December 2025)87 of 100 (industry or sector 50 + size 17 + country 15 + figures on file 5)+ Add
- Viatris Inc.VTRS · 🇺🇸 USASame industry: Pharmaceutical · 7.8× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $22.0 B (Oct 30, 2026) · revenue $14.3 B (year to December 2025)87 of 100 (industry or sector 50 + size 17 + country 15 + figures on file 5)+ Add
- Johnson & JohnsonJNJ · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $652.5 B market cap against $170.7 B · Same country: USAMarket cap $652.5 B (Oct 29, 2026) · revenue $94.2 B (year to December 2025)86 of 100 (industry or sector 50 + size 21 + country 15)+ Add
- AstraZeneca PLCAZN · 🇬🇧 UKSame industry: Pharmaceutical · Similar size: $242.6 B market cap against $170.7 B · Ratios of the last two fiscal years on fileMarket cap $242.6 B (Aug 1, 2026) · revenue $58.7 B (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Elanco Animal Health IncorporatedELAN · 🇺🇸 USASame industry: Pharmaceutical · 15× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $11.3 B (Oct 28, 2026) · revenue $4.7 B (year to December 2025)82 of 100 (industry or sector 50 + size 12 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.